Piramal Pharma Limited
↗Mumbai, India
Piramal Pharma Limited is a globally integrated pharmaceutical company operating as a Contract Development and Manufacturing Organization (CDMO), producer of complex hospital generics/inhalation anesthetics, and consumer healthcare company. The company operates through three divisions: Piramal Pharma Solutions (integrated CDMO), Piramal Critical Care (hospital generics and inhalation anesthetics), and Piramal Consumer Healthcare (OTC products). With 17 manufacturing facilities across North America, Europe, and Asia serving 100+ countries, PPL is the top 3 CDMO in India and 13th globally. The company crossed $1 billion in revenues in FY25, driven by on-patent commercial manufacturing in the CDMO segment and critical care products globally.
CLASSIFICATION
Company Type:CDMO
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:CDMO, Hospital Generics, Consumer Healthcare
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$1B-$1.5B (FY25: $1B+ with 12% YoY growth)
Founded:2022
Ownership:public
Status:operating
FUNDING
Stage:Public Company
Investors:The Carlyle Group (20% stake, INR 3,523.40 Cr investment completed)
STOCK
Exchange:NSE/BSE
Ticker:PPLPHARMA
Market Cap:Estimated $2-2.5B USD (based on ~Rs 24,000Cr valuation post-Carlyle investment)
PIPELINE
Stage:Commercial Manufacturing (primarily services other companies' pipelines)
Lead Drug Stage:As a CDMO, Piramal manufactures on behalf of innovator companies. Notable recent approvals supported: WIDAPLIK (FDA approved June 6, 2025)
Modalities:Small Molecule APIs, Peptide APIs, High-Potency APIs (HPAPIs), Antibody-Drug Conjugates (ADCs), Oral Solid Dosage Forms, Injectable Formulations, Inhalation Anesthetics, Sterile Fill/Finish, Biologics (through Yapan Bio partnership), Gene Therapy (through partnerships), Monoclonal Antibodies (through partnerships)
Trial Phases:-
FDA Approvals:2
CORPORATE STRUCTURE
Subsidiaries:Piramal Pharma Solutions (CDMO division), Piramal Critical Care Limited (Hospital Generics), Piramal Consumer Healthcare, Allergan India Private Limited (49% JV stake, formerly known as Allergan India), Yapan Bio Private Limited (33.33% stake, biologics/vaccines)
Key Partnerships:Carlyle Group (20% strategic investment), AbbVie/Allergan (49% JV - Allergan India Private Limited), Yapan Bio (33.33% stake - biologics development), Plus Therapeutics (CDMO partnership for clinical trial supplies), Multiple pharma innovators (CDMO service contracts)
COMPETITION
Position:Challenger/Leader
Competitors:Thermo Fisher Scientific, Lonza, Catalent Inc., Cambrex Corporation, Recipharm AB, CordenPharma International, Samsung Biologics, Siegfried Holding AG +2 more
LEADERSHIP
Key Executives:
Peter DeYoung - Chief Executive Officer
Vivek Valsaraj - Executive Director
Vibha Paul Rishi - Non-Executive Independent Director
Peter Stevenson - Board Member
Board Members:Peter DeYoung (CEO/Board Member), Vivek Valsaraj (Executive Director), Vibha Paul Rishi, Peter Stevenson
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Piramal Pharma Limited and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Piramal Pharma Limited. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.